Technical Data
ADD1 (Alpha-adducin, Erythrocyte Adducin Subunit alpha, ADDA)
ADD1 is a ubiquitously expressed membrane-skeletal protein localized at spectrin-actin junctions that binds calmodulin and is an in vivo substrate for protein kinase C (PKC) and Rho-associated kinase. ADD1 is a tetramer comprised of either f/g or f/n heterodimers. ADD1 subunits are related in sequence and all contain an N-terminal globular head domain, a neck domain and a C-terminal protease-sensitive tail domain. The tail domains of all ADD1 subunits end with a highly conserved 22-residue myristoylated alanine-rich C kinase substrate (MARCKS)-related domain that has homology to MARCKS protein. It caps the fast-growing ends of actin filaments and also preferentially recruits spectrin to the ends of filaments. Recent observations suggest a role for the protein in cell motility, and as a target for regulation by Rho-dependent and Ca2+-dependent pathways. Human ADD1 gene is mapped to chromosomal region 4p16.3.

Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1:500-1:1000
Optimal dilutions to be determined by the researcher.

Positive Control:
HT-29 cells

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
100ug-20CBlue IceHumanRabbit
As reported
Synthetic non-phosphopeptide corresponding to human ADD1 around the phosphorylation site of serine 726 (T-P-S P-F-L).
Purified by immunoaffinity chromatography.
Supplied as a liquid in PBS (without Mg2+ and Ca2+), pH 7.4, 150mM sodium chloride, 0.02% sodium azide, 50% glycerol.
Recognizes human ADD1. Species Crossreactivity: mouse and rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Matsuoka. Y. et al. Cellular and Molecular Life Sciences. 57:884-895 (2004).